Hyperlipidaemia Education & Atherosclerosis Research Trust UK IA company Ilmlt•d by guar4nt••l R•ght•r•d numb•r: 02631049 Charlty number.. 1003904 Trustees. report and financlal 8tstsmonts for the year ended 28 February 2021 Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK (A company limited by guarantee Cont•nts Page R•forence and admlnl¥tratlvg d•tslls of thg charlty, Its tru•tsos and advls•rs Tru•to0¥' report 2-19 Ind•pond•nt gudltGr8' r•port 20-23 Con•olldat•d 8tstsm•nt of Ilnanclal a¢tlvltlos Con•olldatsd balanc• •hoot 214 Charlty balanco •hgot Con•olldatgd *tat•mont of ¢48h flow• 27 Not•• to the flnanclal •tst•ment• 28.42 Hyporlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Refe￿nce and admlnlstratlve detalls of lh• charity, it8 tru8tee# and advisers for the y•ar •nd•d 28 F&bruary 2021 Trustse• Dr P H Greèn, Chairman Mr S D B0￿Y ACA. Tru8te? Professor E A Hughe$, Trustee M¥ G Howe118, Trustee Ir•signad 24 March 20211 Dr D Neely, Trustee Dr A Ree3. Trustee M6 J Bennett. Twstse Dr R Cramb, Trustee Ms T Kenn8rt8y, Trustee Mr B A Dobson, Trustee Mr A J G￿a￿e8, Trustee Dr P H Green, Trust•• Dr D B N Dattg, Trust?? Mr T M Dlxon, Trustèe Ms S R Myott, Tru¥lge Ire&igned 2 t)ee4mb•r 20201 Mr N R Phipp8, Trustee Ms A Tyler, TruBiee Mr S Handrgan. Tru¥te? lappolnted on 12 March 20201 M¥ N S Kin, Trustee lappoiThted on 12 March 20201 CompAny rogl$tored numbor 02631049 Charlty regl•tsrnd nUM￿r 1003904 Rogl•torod offic• 7 North Ro8d. Mak1eThhead, Bethshlm, SL6 1PE Company ••cr•tsry & ChI•f•x•¢utl￿ offlcer M8 J Payne Indo￿nd•ftt audltorn Moore King8ton Smlth LLP, Davonshlr• Housè, 60 Goswdl Road, London, EC1M 7A0 Annual report incorporating a Directors, Report and Accounts for the year ended 28 February 2021 OBJECTS AND ACTIVITIES Imrodurtlon HEART UK is the UK'S only charity focussed on cholesterol and lipids, lipids being a medlcal term meaning 'blood fav and whilst there are numerous blood fats, cholesterol is the most common. For this reason we will refer in this report to lust cholesterol. but assume this means all blood fats. In 2002 two charitles merBed to form HEART UK. The Brit15h Hyperlipldaemia Association, a health care professlonal focused organisatlon and the Family Heart Association. a patlent focused organisatlon. HEART is an ationym and stands for Hyperlidaemia Educatlon and Athersclerosis Research Trust. As a result of this merger, HEART UK serves patients, thelr families and health care professionals, in addltlon to the general public who may not be aware they have 3 cholesterol Issue. Over half of U K adults have raised cholesterol, putting them at an increased rlsk of heart attacks, stroke5 and vascular dementia. Raised cholesterol is the most common rlsk factor for cardiovascular disease and It can affect anyone, even the youn8 and otherwlse healthv. Cardiovascular dSseasc ICVOI causes almost one.thlrd of all d¢ath$ In thg UK on avera8e. one person dles every three mlnutes Irom CVD. More than 7 million people are living wlth CVD in the UK. Even chlldren can be at risk around I Sn 250 people have the 8enetlc condltSon famlllal hypercholesterolaemla IFHI, whlih leads to hlgh Cholesterol and an Increased flsk of heart dlsease at a youn8 age and even heart attacks In Chlldhood. Currentlyi les5 than IO% of those with FH have been diagnosed, Millions of people with raised cholesterol caused by other factors are similarlv unaware of the risk they face. HEART UK is a re8lStered charity and a company Ilmlted by guarantee. We also have a tradin8 subsidiary. HEART UK Trading Company Limited through which the majority of our corporate sponsorship activity is condtjcted. The charl￿5 object5 a5 set our in our constitution are.. 'To relleve those suffering the effects of heart disease and in particular lipid disorders, familial hyperlipidaemias and related conditions. to promote the relief of sickne55 and the preservation and protection of health by reducing the incldence of vascular disease in the general population of the United Kingdom, to provlde counselling and advice to relatives of those diagnosed with inherited heart disease and to promDte the study of causes, diagnosis and treatment of lipid disorder5 and associated metabolic diseases., Aims and objectives HEART UK provides specialist advlce and expertise to individua15, families and health care professionals working to improve the services available to those who live with high cholesterol. Our single focu5 mean5 we have been able to build a hi8hly influential and collaborative model, bringing specific patient experience and scientific information together to create effective patient communications and influence Government policy. Our focus is entirely on helping people know and understand their cholesterol levels and take appropriate action. We belleve that Investing our limited resource5 on thi5 Qne intervention is the most impactful way of tackling premature cardlovascular dlsease, dlsabllitles, Illness and avoidable earty deaths. We aSm to prevent people getting heart disease and dying from avoldable heart attacks, strokes and Other conditions that high cholesterol can cause. Volunteers Volunteers form a vltal part of HEART UK'5 actlvltles. We tontinue to benefit from a range of volunteers includlng health cafe profe55iona15 5ervin8 on our committees who willingly give up their time to help us be the lead voice on cholesterol and shape the way cholesterol is diagnosed and mana8ed around the UK. We are a150 very lucky to be supported by our Ambassador5 who are the HEART UK voice in their community,. they help ralse awareness of the dangers of cholesterol. We also beneflt from a lot of support from dediczted fundralsers helping to raise funds for our essentlal work. The Trustees wish to extend their sincere thanks to all the volunteers who support HEAR T UK. Our slngle focus means we have built a hlghly influentlal and collaborative model, brlnglng 5peclfSc patlent experlence and scientiflc Information together to create effectlve patlent communications and improving public policy. Publlc Benefit In reporting on the objectives and achievements of the charity, the Trustee5 have given due regard to the Charity Commission guidance on public beneflt under the Charities Act 2011. HEART UK constitutes a public benefit entlty as deflned by FRSIO2. Dlversl uall d Incluslon We have a Diver51ty policy that was last updated in April 2020 and is reviewed every three years. We are committed lo ensuring that the values of equalty, diversty and respect are embedded into everything we do. Tho Charity Governance Codo We aim to abide b the Charit Governance Code. ACHIEVEMENTS AND PERFORMANCE Background information We work closely with lipidolo8ists, scientists, doctors, nurses, pharmacists, dletitians and other health care professlonals across the NHS, plus food companies, medicine manufacturers and across government bodies such as NHS England and Public Health England to ensure patients 8re provided with the information and SLlPPOrt they need to manage cholesterol and live a longer, healthier life. Our focus is malnly on saving lives vla service delivery and educatin8 healthtare professionals. However, we work to advocate on behalf of people wlth high and inherited cholesterol conditions, effecting cruclal change In policy and standards. Our recent en8agement with key opinion leaders resulted in sutcesses over recent years.. ContrlbutSng towards consultations on clinical guldance, from diagnosls through to treatment, long term management and the role of new medication5 Providing evidence & updatin8 NICE guidelines and dissemlnating these to healtheare professionals and advislng on 6uldance documents for healthcare commlssioners Publishing our Statement5 of Care.. setting out best practlce for treating patients are used around the UK and world and Improve patlent outcomes Our FH Days of ActSon resulted in political prioritlsation of FH Our National Cholesterol Month reached many mlllions of people and provlded new videos on FH. fltness workouts and recipes Awaril winnin8 awareness and influencln8 campalgns Influenced the UK Natlonal Screening Committee to revi51t its declslon not to screen very young chlldren In the UK for FH via a robust consultatlon submi5slon wlth research and evldence Over the next ffve years we will continue to build on these successes, ensuring that the NHS delSvers IVS targets published in their NHS Lon6 Term Plan and continues to priorit15e and adequately fund cholesterol related diagnoses and sUPPOrt services. The teom Durlng 2020121 the team adapted extremely qvlckly to the COVID-19 pantlemlc and we all successfully worked from home to seamlessly provlde the sUPPOrt our beneficlaries need in such uncertain tlmes. Providing scientifically bosed, ftictually uccurate information We provlde a range of information both on and offline covering each of the conditions we support. All our information is scientlflcally based and factually accurate. For people who have been identified a5 at risk of or having FH, information Is scarce with GPS potentially unfamiliar with the conditiori and referrals to specialist lipidology consultants whith can involve very lon8 waiting time5. This can be a very anxious tirne, which is not helped by a plethora of confusing and contradictory information available online. HEART UK addresses this issue by working with GP Surgeries and cllnlcs atross the country to offer patients user-friendly, evidence-based and practical information and advice on how to understand and tackle high cholesterol. All our Informatlon and advice is produced by our specialist cardiac nurses and dietician5 and is SUPPOrted by our MedScal, Sclentlflc and Research Committee. Thls information and advice is regularly updated. The most popular leaflets include'urbderstanding Cholesterol, and 'Healthy Eating,, but we a150 provide information specifically for certain groups, such as children with FH. We have booklets aimed at children of different ages living with FH Igenetlcally high cholesterol) to help them understand their condition. We aim to ensure that patlents who have been diasnosed with high cholesterol have access to quality information to explaln and advlse them. We monitor the uptake and re-orders of literature by GP practices as a proxy indicator for this access. We provide literature to over 1,200 GP practices with these practice5 continuing to place reorders for our literature whlch we Supply free of char8e. We know that our literature provision does Increase access to quality Information. Callers to our Cholesterol Helpline frequently report they received our literature vla their GP and are getting in touch as they have further questions- demonstrating both that the need for information exists and that HEAR T UK'S seNices are helping to address this need. '1 udd the HEAR T UK web oddress to m05t of my cllnic letters, which are shared with the GP and potient. Ifind that I don't hove enough tlme to discuss dietary modifACQtion in detuil in on appointment ond occe55 to o speciulist dletltion is limited. I h(7vefound thL7t 51gnpostinq to the webslte Is a very effective component of u virtuol consultt7tion ond thefeedback hos been excellent. My dletetlc colleogues odvlse me thot patient5 ore better Informed if they See potients who have alret7dy accessed the HEAR T UK website.. Dr Dev Datta, Consultont Met(7bolic Ph slcian, Universlt Hos ital o Wules, Curdi The HEART UK Cholesterol Helpline Our dedicated Cholesterol Helpline offers informatlon and support over the phone or by email. The helpline responds to a clear need for advlce in deallng wlth newly diagnosed raised cholesterol or concerns about famlly history of heart disease. Long waiting tlmes for GP appolntments, limited time and Information available from GPS, long referral waitin8 list5 for lipid specialists and a profusion of misinformation on the internet all contribute to a situation where people lack accurate information or tailored advice. People who are worried about raised cholesterol, or not Sure what to do about their cholesterol leve15 often have rowhere to turn for advSce and end up doing nothing- or worse,. relying on inaccurate advice and information from the internet whlch can endanger thelr health. The HEART UK Cholesterol Helpline is uniquely run by expert cardiac nurses and specialist dietitian5, supporting anyone that contacts us to help them manage their cholesterol. In 2020121 over 1,700 people acce55ed our helpline for support, including people newly diagnosed with high cholesterol seeking help to understand their condition and the actions they need to take to ameliorate it. The Helpline also supports people diagnosed with, or who have lost a family member to, the inherited high cholesterol condition, FH. These enquries can be complex and require expert knowledge and profe551onal handling and are often 'time heavv. The Helpline team of specialists provide the information and advice in our literature, on our website, in our social media posts and take part in conferences and webinars, Tadio broadcasts and other PR activities desi8ned to raise awareness of the dangers of high cholesterol and the steps individuals can take to manage it. Our Helpline users tell us how Important our Service Is to them and often support our advocacy and fundraising. "HEAR T UK'S nurse helpline was exceptionally helpful advising me on the correct dietfor my recently diagnosed high cholesterol. I now understand the need of a balanced diet rather thon the extreme low cholesterol diet. Your odvlce is very much appreciated" Helpllne user. Heolthcare proft5sionol support Onllne support for healthcare professionals over 2020121 Throughout the year we provided re8ular, online education and support to both the public and healthcare professionals through our COVID-19-19 webinar series. More than 6,800 people have benefited from these webinars, which were promoted primarily through our own tommunicatlons channels and highlighted the si8nlf5cant level of enBagement of our audience. From our Virtual Llpld Update alone In November 2020, we hosted Ilve via a webinar format to over 300 healthcare professlonals throughout the day. We maintalned more than 200 healthcare professlonals watching Ilve for every session. Based on 235 response5 to our survey= 94.5% reported they were more confidènt dlscussing the topics covered, of which 18.3% were 'much more, confident 98.7% reported they were more knowledgeable on the toplcs covered, of which 21.3% were 'much more, knowledgeable 92.8% agreed our webinar would help to improve their patient care, of whlch 34.5% '5trongly agreed, 91.1% agreed they could implement the knowledge they learned In our webinar, of which 33.2% 'strongly agreed, Additionally. +19.4% Increase in healthcare professional members- now 1,328 sbnce sept 2019 +298% increase in confidence amongst healthcare profe55i0nal following an educational event 93% of healthcare professlonals would improve thelr patlent care and are more confident in discussing topics "HEART UK offer5 excellent webinurs ond I hove recommended them to all ofmy colleagues and Pt7tients. Thank you again for inviting mel" Healthcare Professional Our live, interactive sessions have driven home key healthcare messages an(i gathered vital intelligence from those working on the groijnd. Our webinars have all been delivered Ilve, and a150 recorded to ensure maximum aecessibility for our audience. These recordings are all uploaded to our professional membership area for exclusive access to those who loln our free programme. FH Intellli9ence Network We provide a source of network support through our regular monthly telephone conference calls to bring together health care professiL)nals dealing with FH. They discuss challenges, sha information, best practice and learn from each other. Lipid Interest Group Thls Is a group of over 120 allled health professionals, from FH and apheresis nurses to GP practice nurse5, who meet once a year to network and share information. Once a month they cSrculate a 'round robin, featuring a recent example of thelr work. ThSs proves useful to all. Annual sclentlflc conference With the event of COVID-19 durlnB 2020121, 3lthou8h we were forced to cancel our 2020 Annual Sclentlflc Conference, in July 2021 our Annual Sclentific Conference, whlchls a flagship event and Is widely recognised as THE conference to attend for lipids in the UK, will once again return but for this vear it wlll be vlrtual. Nutrition Academy Our Nutrition Academy is an onllne platform almed at provldlng Information and training to all health care professionals who deliver dletary advlce to Individuals dia8nosed wlth high cholesterol. We have recognised the lack of dSetetlc support In speclalist area5, and the challenge5 in acce55ing these servlces In other areas. This has led to non-dletetlcally trained staff leeling responsible for advisln8 patients. The purpose15 to provlde an onllne centre of excellence to ensure health Care professlonals tan provlde accurate, evldence-based information to their patients about how to manage their condltlon to reduce their risk of cardiovascular dlsease. An advisory panel of experts In the field of nutrltlon and dletetics helps us steer the pro8ramme,' we are currently in the process of reviewin8 funding opportunlties to expènd its remit to Include an onlSne e-learning platlorm. The impact at a personal level- Stephanle's Story A decade ago. Stephanie Dunklevs cholesterol lipid level was found to be raised at 6.ImmollL, but her then GP thought her overall risk of heart disease wa5 low, as she was actlve and otherwise healthy. Year5 later, she discovered that her risk of heart di5ea5e and a heart attack was in fact very high. She told us about her experience and what it has meant for her familv. .1 became increosingly worrled, os my cholesterol level was going up desplte makinL7 chonges to my diet ond lifestyle. Then my sister hod a stroke and no underlying ct7use wjs identified. I discovered HEART UK s website, and read about the genetic condition lomilit71 hypercholesteroloemlo.. I opplied the diugnostic tools on the website to myself and I came out OS POS5ible FH. 41 Just before theflrst Covld lockdown, I suw a different GP ond presented my results. My latest totol cholesterol results hoLI also come bt7ck ot 7.8 mmol/L with 'considerfomlliLII hyperchole5terolaemio'. A5 0 woman, being undi(Jgnosed ond untreoted ot 60 meont l alreudy hod 0 50% chance of havln9 hetirt disease. To uvoid delay, whilst waitingfor a lipid clinlc appointment which took o year, I was prescrlbed 5totin5. When 15aw the Llpid ConsuItLint, he ugreed with the assessment oApossible FH as my dod died af 61 ond my paternal grundfather hod olso died of a heart ottack at 45 yr5. Further blood test5 dlscovered that l 0150 have o very High Lipoprotein (oj, tinother generic bloodfot related condition thotfurther increL75es your risk of cardiovosculor dlseose. l used HEART UK'5 web51te and helpline 5everol tlmes during the pandemic to learn t7bout FH, ond Hl¢h Llpoproteln (u). It helped Pfvpui¥fvi iiiy ipiediiul rjppoiiitnients and to manage my condltlon. The HEAR T UK nurse wtis sensitive and receptive. and I tfU5ted her expertlse and knowledge of cholesterol ond heart heolth. The nurse reossured me that I w05 asking the rlght questlons und I wos seelng the right people. I do not hove children but discu55ions obout genetic testing have commenced. Meanwhile, my tidult nephews ond nieces hove been odvised to get u cholesterol test. Thonkfully, l om now on treotment ond my risk of cGrrdiovascular dlseuse 15 now significantly reduced. Recentlyi I was suddened when a neighbour oged 63 who rnoy hove hod FH died suddenlv, de5Pltefeelingflt ond well. Stories like thi5 bring it home. If you huve on underlying genetlc c(JUse of hlgh cholesterol then you can Still develop heurt diseu5e, even if you hL7ve a healthy diet und arefit und octlve., The Impact on HEART UK of coronovlrus- COVID-19 HEART UK'S fundraSsing has, as wlth other charitles, been impacted by coronavirus. A number of our fundraising events have been cancelled due to social distancing measures to prevent the spread of the virus. Despite the challenges presented by coronavirus for the charity, the demand and need for our Services have become even greater. Coronaviru5 present5 an additional risk for those with heart disease. People living with rarer lipid disorders are presented with additional risks, often needing to be shielded. Services both at GP clinic5 and specialist services at lipid clinics, including more intensive treatment centres providing aphere5is have very limited services or indeed have stopped. In response to thi5 crisis, HEART UK is providing additional seryices for patients, the public and health care professionals. Workin8 to improve the level and quality of information available to individuals about cholesterol, CVD and the Impact of COVID.19 on servlces they receive., Working to ensure health care professlonals are equipped to identlfy and support those at rlsk., Working to ensure that at-risk patlents tontinue to receive Support while NHS services are redeployed and explore alternative opportunitles to access treatment; Hostlng new and general cardiovascular rlsk land other related condltSonsl Snformatlon for COVID-19 Publlshed an expert poslton statement on managlng hyperllpldaemla in patients with COVID-19 Specialist advice regardin8 shieldin8 for: Homozygous FH Patlents on apheresSs, whlch has been dlscontlnued Transplants Pregnancy and CVD Understanding 'hiBh'/'very high, rlsk: Famllial Hypercholesterolaemla Hlgh LPlal Comorbiditie5 Rarer lipid condltlons We are providin8 more specialist online and remote information to support patients with high cholesterol and additionally accelerate thls crisis programme for those at very hlgh risk of severe Illness from coronavirus ICOVID-191. This includes people with diabetes and those with heart and circulatory diseases who need to undertake additional measures to mlnlmise thelr risk. This support supplement5 the 5ervice5 that have been diverted and are currently not available from the NHS. MaJor Achlevements During 2020121. HEART UK has had much to celebrate with our campaigning. This has been as part of a programme of actlvltles and building on last yeai's success, ensuring that cholesterol and familial hypercholesterolaemia IFHI were included in the NHS England Long Term Plan. We were instrumental in getting a target for increasing the 15,000 FH cases already known to 62,SOO by 2024. Thank5 to HEART UK. this Is the only 5-year target in the Long Term Plan as the remainder are 10 vears. We have been making significant efforts over the last 4 year5 to get FH identified as early as possSble. HEART UK is the only charity championing thi5 5lnce It was proven to be so succe55ful in a research study of 10,095 children and published in 2016. We believe screenin8 children for FH should be a national Screening programme. Testing chlldren early will lead to whole famlly screening. We are delighted to say that NHS En8land ha5 agreed to pilot this approach in England. We have made significant Inroads for one place for a lifelong reglster for FH. This will help the health systems across the UK to identify FH In other famlly members in a systematic way which is both life and cost-saving and we had commltment from the Chief Executive of the NHS to investment in a new system. HEART UK contributes to many health consultations carried out by various agenEles, Including NICE and other simllar offices across all countries of the UK. One such consultation was about the NHS Health Check5. We have been champlonin8 for this to be reduced from a start age of 40 years old to 30 years old In high cardiovascular risk areas. We also want it more accessible for people to Bet a cholesterol test and identlfy other health Issues In pl)ces outside of the GP practlce* particularly in community pharmacists who play a vltal role in the population'5 health. We have kept the pressure on the system to prioritlse cholesterol testing and reportlng and we are pleased to say that we have had success in this area wSth the introduction of a new audit in GP practlces called CVD Prevent. FH Day of Action 2021 HEART UK15 the only tharity campaigning for people affected by FH and has been instrumental In bringin8 attention to the conditlon with MPS and the NHS. We have successfully campal8ned for improvements to the way FH service5 are developed and continue to work with the NHS to help identify, treat and support more people affected by FH than ever before. Thanks to your support the FH Day of Actlon resulted In over 45 letter5 sent to MPS, questions asked in Parliament about FH seNices and many conversations with MPS. Correspondence between Prlti Patel MP and Professor Stephen Powis, National Medical Dlrector NHS England who states" . we are investing in a programme to test the design and implementation of a child parent screening clinical pathway,. this approach will form part of unified programme, including GP case finding, that will support the FH ambition in the NHS Long Terrn Plan." io A reply to Theresa May MP from Matt Hancock MP, Secretary of State for Hea￿h and 5oclal Care who 5ay5. 1 completely understand your con￿rn5 about holding the NHS to account on its commitment to increase detection of FH to 25 per cent by 2024.1 am grateful that you have taken the time to write about this important Issue... We have established an FH Expert Adv150ry Group, of which Heart UK is part, and collectlvely we are driving this agenda forward. A similar letter from Jo Churchill, Parliamentary Under-secretary of State for Preventlon, Public Health and Primary Care A letter from Simon Steven5, NHS Chief Executive making a commitment of £5LKS,000 to enable a pllot in seven areas of England to screen 30,CQO chlldren for FH A further commltment to an additlonal £335,000 for the NHS to help detect FH and Investment In a slngle, national re8lStry for FH Awareness ralslng Responding to the media Throughout the year we featured In numerous press articles, journals and magazlne5 including the Dally Telegraph, Express and The Ma51 on Sunday in addition to Waltr05e magazine and It5 Customer newpaper over National Cholesterol Month. Cholesterol e-News Subscrlptlon to our popular e-news ha5 more than doubled in the past 12 months from lust over 15,000 subscribers to well over 33,000 people. The newsletter includes features on healthier eatlng, being more active and promoting fundralslng aetlvlties. According to our servlce provider, Mailchimp, the open rate is almost twice as high as other slmilar newsletters ènd the number of people clicking on links on news items is more than three tlmes higher Nutlonul Cholesterol Monrh In addition to producing new videos for families affected by FH in collaboration with The Newcastle Upon Tyne NHS Trust and keep fit videos with Anytime Fltness, the maln focus for National Cholestrol Month in 2020 was the 'Talk about cholesterol, public awareness campalgn. The purpose of the campalgn was to target messages via soclal medla to areas of the country where cardiovascular dlsease was higher. The campaign Set out to reach an ambitious I million people during the month in a targeted and tailored way, u51WI8 Facebook. By the end of the month the campaign had exceeded our expectations and over 3 mllllon people viewed the campaign mes5age5. li Removing the barriers to employment Some people are reluctant to get an FH Benetic test or to 8et their children tested because of how it may affect their employment, particularly in the armed services. If FH is mana8ed well and the per50n with FH 15 on treatment, then they are otherwlse usually fit and healthy. As a result, there 15 no reason to be excluded from the armed Servi￿$. This was brought up with the Strategic Command Headquarters Defen￿ Medlcal Servlces for the armed forces, and along with the help of Prof. Steve Humphrle5, Emeritus Professor of Cardiovascular Genetics at the Institute Cardiovascular Stience, UCL it was confirmed that people with FH, providing that their medication Is working effectively as it usually would, are now f and able to serve In the armed force5. Leoder5hip HEART UK developed and leads a network of heart and circulatory disease charltles, Including Stroke Associatlon, Cardiomyopathy UK, ArrhythmSa Alliance and Blood Pressure UK. The purpose of the network 55 to co-operate on mutually beneficial initiatlve51 partlcularly campaSgn and policv focussed. Collaboratlng Included a response to the NHS Health Check consultation and a thought piece on the impact of COVID-19 and the lockdown on serylces published In the Health Servlce Journal. PRINCIPLE FUNDING HEART UK'S approach to fundraising is largely relationship led, throuBh: Individual 8iving Sports and challenges Legacies Corporate partnerships, including food, 8yms, clothes recycling, diagnostlcs and pharmaceutical companles HEART UK has a tommerclal partlclpator relationship with our food partners Whe￿bY a company will apply to use our product approval logo on their products. These applications are assessed by our expert Product Approval Task and Finish Group against a stringent process and a very strict criteria. We also have commercial participator relatlonshlps with companie5 we have entered In a paitnership with. HEART UK do not carry out street collections or house-to-house fundralsin81 Other than bag drop5 for one of the clothes collection services. HEART UK uses third party companies to asslst U5 With our fundraising, including our clothes collection services,. sports and challenge5; payroll giving and legacy. HEART UK has a safeguarding and childlvulnerable adults protection pollcy. This was updated in April 2021 and Is reviewed every two years. The Board of Trustees have all our policies in a Trustee manual and are informed when there is an update and requlred to familiari5e themselves with each policy. The staff are required to familiarise themselves Wlth all our policies each year and are provided with regular trainin8. 12 HEART UK is registered wlth the Fundraising Regulator. HEAR T UK complies with the Charities Art in regard to fundraising and in addition puts the privacy of our supporter data at the heart of everything we do. We manage personal data respettfully and responsibly in accordance with our published privacy policy. HEART UK received an estimated 14 complalnts as50clated with fundralsingi all of which were relating to the clothes recycling scheme and mostly were around the bag5 not beins collected. in this financial year. This Is a very low figure for the sector. Nevertheless, we are committed to studyin8 any expression of dissatlsfaction and Identifyin8 ways to improve. Our fundraising team look into each complaint and we do all we can to resolve the matter and ensure supporters are happy with our work. Our complaint procedure is publically avallable on our web51te. Without the fundraislng support we would not be able to operate and we are incredlbly grateful for every penny that is donated helping US to truly save lives and keep families together. RISK MANAGEMENT The Trustees have assessed the major rlsks to which HEART UK Is exposed and are satisfied that systems are established to mitigate the charity's exposure to those risks. These risk5 are detailed on a r55k reg55ter, reviewed quarterly by our Flnance and Risk Committee and annually by our Board of Trustees. The blg8est risks currently featurlng on our register are: Cyber fraud. Many chaiities are experienclng cyber fraud and this has 518nificantly increased over the last year. We consider we have robust procedures in place to best avold thls and have developed a Specific cyber fraud policy. Consequences of COVID.19. We are respondlng by ensurin8 we provide the necessary support to our beneficiaries. We are regularly revlewing the funding sltuation. by havin8 more regular Finance and Risk Commlttee meetln8S. Fundlng. Thls has been impacted by the COVID-19 51tuation. The team have worked hard to acce$5 fundin6 both emergency and ongolng. We also have a constant view on cashflow. FINANCIAL REVIEW Income for the year ended 28 February 2021 totalled £776.1101£1,132,165 In 20191201 Expenditure on raislng funds was £304,0541£515,795 in 20191201 and charltable activity spending wa5 £562,2781£672,075 in 20191201. Of partlcular note.. We received one large legacy durlng the 2019120 year totalling £180,000, with a further estimated amout of £40,000 still to follow. We leel very grateful to Ruby Ada Watts for thinkin8 about HEART UK in her wlll and considering the tremendous support we can provide to our beneficiarie5 Wlth such a huge contribution to our essential work. We have reshaped how we work with our food Corporate partners. 13 INVESTMENT POLICY Under the Memorandum and Articles of As50Clation, the charity has the power to invest In any way the Trustees see fit. The policy of the charity Is to adopt a low-risk strategy at present. We have one investment whlch is low risk with no investment in tobacco, alcohol or arms. RESERVES POLICY The reserves policy is Set by the Board of Trustees and reviewed annually. We aim to hold free reseryes in the range of 6- 9 months, worth of operating expenditure. Our free reserves at the year end totalled £493,494 which represents just under 6 months. In the light of the effects of COVID-19 highlighted elsewhere, our free reserves will fall below our operating guidelines during the next 12 month5. The Board of Trustee5 are fully aware of thls and this position will continue to be monltored by the Finance and Rlsk Committee and the Board throughout this period. PLANS FQR THE FUTURE Our vlsSon1s to.. Prevent early disease and deaths from cholesterol and other blood fat Ilipldl condStlons in the UK. Weaim: To increase the number of people identified In the UK wlth Inherited lipld conditions from 2 Jf,000 to 50,000 by 2023. For people to know and understand their cholesterol and other blood fat Illpidl levels and take appropriate action. We Intend on aehleving this by.. Influencing health and polltlcal systems to ensure 3 focus on cardiovascular disease preventlon with an implementation plan to identify and treat people wlth hS8h cholesterol Influence lipld data to be captured and reported Educate health care professionals & the publlc about inherited and preventable lipld condltions and actlons they can take Ralse awareness of Inherited and non Inherlted1Spid conditions thereby empowerlng people to take action Support those dlagnosed & their familie5 and support those diagnosed to take appropriate action Raise funds to enable Lts to deliver our activities Durin8 2021122 we will-. Continue with our Cholesterol Helpline enguring we provide the best ways for people to get In touch wSth us Regularly review our information provided to erbsure it 15 UP to date Continue to build our communication channels to further increase our reach and Influence, particularly digital and online Publish appropriate expert papers in order to ensure best practice treatment and management of lipid patients 14 Continue to educate the publici patients, families and healthcare professionals treating patients with lipids Continue to ensure CVD is a key priorlty for the Govemment Continue to lobby for FH to be identified as early as possible,. in children and adults Continue to lobby for data to be captured and published by NHS England and Public Health England so we know exactly what the picture looks like with lipid patients both locally and nationally STRUCTURE, GOVERNANCE ANO MANAGEMENT The charity IS governed by a Board of Trustees who are legal members and also directors of the charity for the purposes of the Companles Act. The Board sets the Strategic directlon of the charitv ensuring that the charitable purposes are met. The Board of Trustee5 delegate the day to day running of the charlty to the Chief Executive. HEART UK conslders each of the Trustees to be independent In character and judgement,. and understands that they have no relationships that are Ilkely to affect, Qr could appear to èffect, thelr judgements wlth regard to HEART UK. Declaratlons of interest are required from new Trustees upon appolntment, annually and every meetin8 of the Board requSres that any new interests are declared. No remuneratlon Is provided except for reasonable travel and subsistence costs. These costs totalled £0 during 20201211£2,365 in 20191201. During 2020121 we had changes to the board of trustees with Sophie Myott and Gaenor Howe115 stepping down. There are a number of committees and task and flnlsh groups that serve the Board of Trustees to assist in the delivery of our oblectSve5', Flnonce and Risk Key areas for thls committee are: To be re5pon5ible for financial and 8eneral business affairs of the charity including: Risk Management Flnanclal Control Management Audlt and presenting flnal accounts to the AGM followlng Board approval. Reviewing annual accounts prior to Board and then AGM approval. Communications and Fundroising Key areas for this committee are: To oversee our communications and channels used To oversee our fundraising activities 15 The Medical andS¢ientific Resetirch Committee (MS&R) Oversees the Annual Conference, the development of research and speciality training pro8rammes, cllnical guideline5 development and creatin8 and updating our information. The Healthcare Committee Key areas of interest.. Provldes up-to-date informatlon to health care profe5siona15 who care for patients and thelr families with lipid disorders. They co-organ15e the Health Care and Patlent part of the Annual Conference. Campaiqning Advlses on public affair5 and pollcy activities to highlight the importance of cholesterol and CVD. T k and firtlsh rou These groups meet when there Is a task to be actioned.. Llpoproteln Aphere515 Key area5 of interest,. To promulgate guidance for the clinical Indlcation for Ilpoprotein aphe￿51$. To review and recommend the criterla of efficacy of performance in the UK (Assessment to be based on Reglstry data jointly formed by HEART UK and the Royal ColleRe of Phy5iciansl. To educhte society in general about Apheresis as a treatment. FH Registry Advisory Group Th55 group oversees the Governance of the FH Registrv. confe￿nce orgonlslng Thls group organises the annual scientific conference usually held in Juneljuly over a 3 day period. Grnnt Aword5 Thls group oversee our grant scheme and review applications. Educotion This group oversee our education programmes. Policy Development Operates to develop, oversee and review the pollcies of the organlsatlon. Product Approval For approved commercial produrts that bear the HEART UK1080. The group operates within an ethical and scientific policy framework to evaluate products for approval. 16 CVD Collabort7tive This group meet to drlve forward particular campaigns around changing health policy for the NHS and Govemment. UK Nationol Screening Committee Thls group drives forward our campalgn for the Introductlon of chlld-parent screening for FH. The Simon 8roome Steering Commlttee Isecretorlotj Is responsible for directing research based on a national cohort of over 3,500 patients with familial hypercholesterolaemia land severe hypertriglyceridaemial. STAFF A senlor leadershlp team, conslsting of the Chief Executive and Heads of External Affairs and Healthcare allows for distributlon of organisational responsibility. The Chief Éxecutive has particular responsibility for issues relatlng to Bovernance and for the financial management of the or8anisation. HEART UK has 9 permanent members of Staff, 5 full time and 4 part tlme18 full time equivalentl. The Trustees would like to record thelr appreciatlon of efforts of the staff, who have agaln made an enourmous contributSon to the succe55 of HEART UK during the year. PAY AND REMUNERATION The Finance and Risk Committee review the 5alar1e5 of the staff and advlse the 8oard on anv recommended changes, Thi51s dlctated by market forces and affordability. A new people management framework has been developed and Is beln8 introduced in March 2021. The remuneratlon of the Chlef Executive is assessed by the Board of Trustees. Thls includes conducting a 360 degree a5sessment,' internally and externally, market forces, performance and affordability. AUDITOR The auditor5 of the charity and trading company are reviewed by our Board of Trustees and appointed as appropriate at OUT Annual General Meeting. TRUSTEE APPOINTMENT. INDUCTION AND TRAINING Trustees are appointed in accordance with HEART VK'S Constit￿lon, taklng into account the benefits of appointing a person who is able, by virtue of their personal or professlonal qualifications, to make a contrlbutlon to the pursuit of the objects or the management of the charity. Trustees consider the skills gap on the Board of TTu5tees. Trustee vacancies are openly advertised and recruited following an interview and selection process and then proposed and appointed at the AGM. 17 HEART UK undertakes an induction programme for all new trustees, including induction materia15 relating to its purpose and finances, the powers of tmtees and information about the day to day runnlng of the organisation. Key documents are provided, such a5 the constitution, accounts, min4Jtes of recent meeting5 and policies. Trustee5 continue to be supported throu6h ongoing training. SMALL COMPANIES REGIME This report has been prepared in accordance wlth the special provi5ion5 relating to small companles within Part 15 of the Companie5 Act 2006 CONSIDERATION OF GOING CONCERN The company continue5 to adopt the going concern basis in preparing Its flnanclal statements. The trustees have asse55ed whether the use of the BoinB concern bas15 is approprlate and have considered possible events or conditions that might cast significant doubt on the ability of the company to continue as a going concern. The trustees have made thls assessment for a period of at least one year from the date of approval of the financial statements. In particular the trustees have considered the company's forecasts and projections and have taken account of the Coronavirus pandemic. As part of the going concern review the trustees prepared a detailed, forward-looking ash flow scenario, based on the most rea115tic assumptlons avallable at the time. In this scenarlo the company had adequate resources to continue in operatlon for at least twelve months from the approval of the flnancial statement5. STATÉMENT OF TRUSTEES. RESPONSIBILITIES The Trustees (who a￿ also diiector5 of company for the purpose of company lawl are responslb1e for preparing the trustees, report and the financial statements In accordance with applicable law and United Kingdom Accounting Standards Iunited Klngdom Generally Accepted Accounting Practice). Company law requires the Trustee5 to prepare financlal statements for each financial year which give a true and falr view ol the state of affairs of the charitable company and the group and of the incoming resource5. including the Income and expenditure of the charitable group for that period. In preparing these financial statements, the Trustees are required to: select Suitable accounting policies and then apply them consistently,. make judgments and estlmates that are reasonable and prudent- state whether applicable UK Actounti ng Standards have been followed, Subject to any materSal departure5 disclosed and explained in the financial statements,. prepare the financial statements on the 8oing concern basis unless it Is inappropriate to presume that the charity will continue in business., and observe the methods and principle5 in the Charitles SORP. The Trustees are responsible for keepinE proper accounting records that disclose with reasonable accuracy at any time the financial p091tion of the charitable company and enable them to ensure that the flnancial statements comply with the Companies Act 2006. They are also responsible for 5afeguardin8 the as5et5 of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other i¥regularities. 18 AUDIT INFORMATION SO far as each of the Trustees at the time the Trustees, report is approved is aware- there is no relevant information of which the auditors are unaware,. and they have taken all relevant steps they ought to have taken to make themselves aware of anv relevant audit information and to establish that the audltors are aware of that information. AUDITORS A resolution for the appointment of auditors will be put to the forthcoming AGM. THANKS FROM THE CHAIR OF TRUSTEES I would like to extend my person313nd sincere thanks to our dedScated and highly commltted and capable Staff at HEART UK, to my Board of Trustees, our Committee members, Ambassadors and volunteers who contlnue to glve thelr valuable time, commitment and amazlng contributions to help HEART UK truly dellver a world class seNlce for our beneflclarles. Authorlsed by the Trustees on 17 June 2021 and slgned an thèlr ￿h¥ll bv: Dr Peter Green, Chalr 19 Hyperlipidagmia Education Atherosclerosis Research Trust UK ltrading as HEART UK) {A company limited by guarantee) Independent Auditorn. Report to the trustse8 ot HEART UK Oplnlon We have audited the finanoal statement5 of Hyperlipidaemia Educabon Alheros¢lerosls Rèsearch Trust UK Ith8 'CDrnpany'l for the year ended 28 February 2021 which compris8 the Con30lidateJ St8temenl of Financial Ath'vities. th8 Group and Parent Chantable Company Balan￿ Sheots. lh& Ctsnsolidat8d Statement ol CaBh Flows and notes to the financial stal8m6nts, including a summary of significant accoun￿'ng policies The finan￿31 r6porting framework that has ba•n applied in their preparation is appllc8ble law and United ￿.￿gdoM A¢tsunting Standard5 Iunited Kingdom Generally Accepted Ac¢ounb"rrfJ Pfgcts'cel induding FRS 102 'Th$ Flnancial Reportino Stsndard ApOliCab￿ in the UK and Ireland" In our oplnion the financi81 $tat&m&ni8, giv8 8 trt￿ and fair view of thè 8iat8 of tha group's and the parent charitable company's affairs as a128 Fabruary 2021 and of the 9roup's Incoming resources and applieatlon ol msources, including its Income and exoendilure. lor thè vear then and8d. have been propèrly prepored in accordance wlh Uni19d Kingdom Gererally Accepted Accoun￿n9 Pr8CtIc8,' have been prepar￿ In accordance with the r8quirgments of th• Compan186 Act 2006 and the Ch4rib'•s Aet 81818 for oplnlon Wè conducted our audit in accordance with Intsrnalional Standards on Audit'ng IUKI I"ISAs IUKI'I 8nd applicable law. Our responslbllitlas und8f those standard5 are further d¢¥cribed In the auditors, ￿SpOnsIbl11t￿lS lor the auclit of the finan¢ial statements 3eclon ol our ￿POrt. We ar6 Ind8pendent ol ttte ch8rftsble wmpany In accordance with the 8thlcg1 requirements that are relevant lo our audll ol the financial stslernonts in th8 UK. including the FRC'J Etrieal Standard, and we hav• fulfillèd our other 8lhical re6pon3ibili¢ie5 in 8ccordanct wlth these requirèmènts. We believe that the audll &vid•nce ￿ hgve obtained is suffi¢iènt and appropriate to tyovide 8 b8318 f¢r our opinion. Conclu$lon• r+latlnsJ to oolno concern In auditing the fin8nci85 ¥talements, wo have concluded that thè tru8taes' us• ol the going ¢oneem ba$1$ ol accountlng in tho WéP8ration of the financial 8tatwngnts 1$ approprlate. 888ed on the work w• have perforrned, we havè not Identified any material uncertaintieB relatlng to ov•nts or conditlons th8t. ind1￿4￿911Y or collects"vely, may cast $i9nificant doubl on th8 charitable ¢ompany's ability to linue 9$ 8 golng concom for a poriod ol 9119gSt ￿1ve months fvorn when th? financial slatem6nls are authorised lor issué. Our re8ponsibilitie3 and th& r•8ponsibIl￿8$ of Ihè tru818è$ wilh w$p•et to going concem are de$¢ribed in the relevant seclon¥ of thls réport. Oth•r Informatlon The other Inforrn8tion ¢ompdse5 the Inforrnalion included In thg annual report, ¢trèr than th8 Ilnandal &tslemenl8 and our auditors. r•port Ihereon Thè tnJste8s ara ￿spOnsible for the other information. Our opinion on the financial statemènts does not cover the oth*r inlorm8tion and, except to the extènt tsthèrwsa èxpliutly Stated in ¢ur rèport, wa do not express 8ny form ol 8ssuranca concluslon Ihereon. In ¢tynnèction with audit of the fin8ncial statements, our regponsibility 13 to read the othar information qnd, in doing so, con8ider whether the other information is materially inconsistènt with the financlal stalgments or our knowladga obtained in the audit or otherwise •￿earS to be rnalerialty mi5stst¢d. If ￿ identify such rnatsri81 inconslslencies or appargnt material misstalernents, we are required to detemine whether there is 8 rnatoriol mi5Statement in the fin8ncial stgtemenls or 8 materi81 misstatern9nl of tho Dther inforrnation. If, bas8d On tha work we have performed. WÈ condud8 that there is a rnaterial ml8stat&mènt of this other inforrnab'on,. we are rI￿111r￿A In r•Mrt Ihrth• We have nothing to rep¢rt In thls regard. 20 Hyperlipidaemia Education Atherosclerosis Rosear¢h Trust UK (trading as HEART UK (A company limited by guarantee) Independent Auditors. Roport to the trustoes of HEART UK Oplnlon on other matt•rs pr•serlb•d by tho Compan1•6 Act 2006 In our opinion, based on th? work undertaken in the cour3e of Ihg 8udil' the inform8tion givan in th8 Irust8es' annual report for th8 financial year for which th8 financial statements are prepared is consistent with the financial statements., and thé tru$taa$' annu81 raport havo boan prgparod in 8¢cordance wlh opplicable18gal roquirèmènts. Mattsr• on whlch we are requlred ¢0 report by oxceptlon In the light of the knowledgg and understanding of the group and parent charbtable company and it6 environrn8nt obtained in the course ol the audiL we have not identified rnaterial misstatements in the trustees, annual reporL We h8ve nothing to ￿port in respect of the followirG maltsrs where the Cornpanies Act 2￿6 and the Charrties Act 2011 require u3 to report lo youll. In our opinion.. the parent charitable company has not kept adequate and sufficient accountr'ng records, or ieturns adequate for our audit have not been received from branches not visited by u6.. or the parent charitable company's finanoal stat•m8nts ar• not in agraamènt ￿th the gccounts'ng w¢ord8 and returns.. or ertain di$cl¢$urès of Irusleés. remuneration Jpecified by law ar¢ not rnad¢". or wa hav$ not rè¢èiv*d 811 tha 1nlormats.on and oxplan8lion$ w& roquire for our audit. the Iru$tees were n¢1 8llts.tlod to prgP8r& the financ181 st8t8rnent8 irt 8¢¢ord8n¢* wllh the $rnall ¢omp8nltr$ règlm• and take advantagè ol thè small companiès èxamplion In prnparing thè Tr¢Jst*as' Annual Rèport and from prepgring a $lratsgic r&port, R•*pon•lbllltl•i of tru•t••• As explained more fully in the slalemenl ol tru$tee$' r8spon$ibllilies $01 out on page 17, tre Iruslee$ (who 8 8180 tho direclor8 of Ih? th¥ritsbl* ¢ornpany for the purpose3 of ¢C￿panY lawl are responsibl¥ lor the preparalon of Ihg finan&81 plalgmenl$ and for being 8al¥fied that th9y give 8 true and falr view, and lor Buch Internal control as the trustoès rJalèm)Ina is nècèssary lo anablè the pwp8ralion ¢1 fi'nan¢ial 8talements Ihal are Irso from m8teri81 misstsloment, whether due to frgud or •rror. In pr8paring th8 financial stst8m8nts, th8 trustee8 are responsible lor ass8sslng the group and parent chgritsbl8 compony's ability to conts.nue as a going concern, di3closing, as applicable, matters relatsd to going concern and U81ry the golng concern basis of accounting unle88 the trusteas elther Intsnd to Iiquidale the group or parent charitsbb company or to cease operations, or havo no rea1istlc alternat"V8 but to do 50. Audltors. r••pDn•lbllltl•8 lor th• Aud￿ ol th• nn•ncl•l •t•¢•m•nts We have been appointed as auditor under Ihe Companies Act 200e and section 1S1 of the Charities Act 2011 4nd report In accordance with those Acts. Our objectives are lo obtain reasonable assurance about whether Ihe finanaal statements as a whole are fr88 from material misgtatemenl. thether due to fraud or error, and to Issue an auditors, ￿port that includes our opinion. Reasonable assurance is a high ￿Ve1 DI assurance, but Is not a guar8ntee that an 8udit conducted in •cLordance with ISAS IUKI will always detect a material rnis5taiement when it exists. Mi55tatements can arisè from fraud or error and are considered material il, individually or in aggregate, they could reasonably be expecied to Infl￿nCe the econornic decisions of users tsken on the basis of these financ4815tstementg Irrogularits'es. Induding fraud. are instances of non-compliancA with laws and regulations. We design procedures in line with our responsibilities. ouilined above, to detect Material misstatements in resp8Ct of irregUlar￿e3, includirrtJ frathy. The extent to which our procedures a￿ capable ofdelecting irregularib'e5, indudiro fraud is 21 Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) IA company limited by guarantee) Indepondènt Audltors, Report to th• trustse8 of HEART UK Audltor•' ro#ptsnsibIl￿•Y forth• Audit ol th• flnanelal statsm•nts Icontlnuedl Expl•n¥tlon *$ to what •xt•nt th• audlt was ¢onsld•rod eapabl• ot d•t•etlng Sffeuulirltle>, Includlng fraud The obiectlves ol our aud￿ in respacl ol fraud, 8re', lo identify and assess Ihe risk8 01 rnaterial misstatement of tha financial slatsments due lo fraud.. to obtain sufficient appropriate audit evidence regarding the assessed risks ol material misstalemenl due to fraud, through designing and implementing appropriate r85pon5e5 10 those assessed risks., and to respond appropriately lo Instance3 of fraud or Yusptsctod fraud Idèn¢ified durfng Audit. Howev8r. th8 prirn8ry responsibility for the prevention and delects'on ol fraud rests with both manoggmenl and those charged with govèrnaneo of tho eh8rit8blè eomp8ny. Our approach w85 86 ltsllow$'. We oblair*d an undèrstanding ol the légal and rÉgul810ry rèqulrefflanls applie8bl8 to the tharitab10 company and considered that the most si9nificant ar¢ Ithg Comwni•$ A¢1 20Cfj, th? Ch8rilios Act 2011, thè Charity SORP. 8nd UK Iin8n¢i81 reporting ¥tzndards a$ i$$u•d by th¥ Financial Reporting Council We obtained an understanding of hgw the charitable COrnPBny cornplles wblh these ￿quIr•m￿nIS by dis¢u¥$ions with m8n8gemant and thosè chargèd with govamanea. Wa ass&ss•d tho risk ol mat8rial rnisstatém•nt ol tho financial stat•m8nts. including the risk ol mal8rial m1SStat•m8nt due lo fraud and how rt might occur, by hO￿ing discussions with management and those charged with governan￿. We inqulr8d ol management and those charged with govern&nce B8 to any known Instsnces ol non- compliance or suJpo¢led nonn. forgery, intentional omissions, misrepre5entalions, or the override of Internal control. Obtain ?n under5tsnding ¢1 Internal control r¢l¥v8nl lo the audit in ¢rdor lo d¥$on audit procedures that are 8ppropn8te in the circurn5tance5. but not tor the purp0585 01 &xpres5ing an opinion on the eff8thv•n•ss ol the group and parent eharitable company's Internal control. Evaluate tho appropriateness of accounting pollcies used and the reasonablen8ss of accounting estimates and ralatèd diselosurès mad8 by the trustees. Conclude on the appropriateness of the tru¥tees' use ofthe going concern ba515 01 accountin9 and, basgd on the audit evidence obt8ined, whether 8 mal8ri81 uncert8inty exists related to events or conditions that may caBt significant doubt on the group and parent charitable company's ability to continu8 as a going concèm. 11 we conCl￿e that a material urtèrtainty exi$tS, W9 ale requir8d to draw atsntion in oui auditor's report to the related dis¢losurg$ in tre financial stat8rn8n15 or. if $u¢h disc105ures ar¢ inadequ8ts. to modify our opiniDn. Our condu510nS 8r8 based on the audit evide￿8 obtainèd up to the d8t• of our auditorfs report. However, future events or conditlons may cause the group or parent charitable company to cease to conts.nue as a nninn r.rsnrAm 22 Hyperlipidaemia Education Ath•rosclarosi8 Rasearch Trust UK (trading as HEART UK (A company limited by guarantse) Ind•pondènt Audltors, Roport to tho tru$ts•s of HEART UK Audltors, respon•lbIll￿oS forth• audlt of th• flnanelal *tAt•m•nt• leontlnuodl Evaluate the overall presentation, structure and content ol the financial stat•m•nts. including the di8dosur8J, and whether the linancAal ststements rewasant the undwlwng tranSac￿On8 ar￿ èvènts In a m8nn*T that ¥¢higv¢$ Igir pres?ntstion. Obtain suffici¢nt appropriat8 8udil emdence regarding the financial infomiation of the entiti•$ or businèss cbvities within th8 group to expre85 an opinion on the consolidate(I financial statements. We are rèsponsibb l)r the ¢Jir9¢Jon, supervislon and performanc8 ol the group audit. We remain solely responsible for our 8udbt Wè communi¢at• with those ¢harged wlh governance regarding, among other matters, the planned scow 8Th1 tlming ol the 8nd $ignifi¢ant 8ud(( finding3, induding any significant delicierrie6 in intem81 control that Idenlfy durfno our audlt U•• olthls rsport This raport Is mad8 501ely 1¢ thé charitAblJ company'3 m•Jmbor3, 85 a body. in accordance with Chapt8r 3 of Part 18 ol the Companiès Ael 20C6 and, in r¢spe¢l ol the consolidated financial statements, to th8 charitls trustees, a8 a body, In accordanca ￿th Chapt•r 3 01 Part 8 ¢1 the Ch8riti&s Act 2011. Our budit work ha8 bgen undertaken so that wa might stat& to the charitabl& company's m•mb¥rs and tru6teeB those matters whlch we are required lo stste lo them in an auditor's report and lor no othar purpos•. To the lullèst èxtent pÈrrnittÈd by law, we do not accept or as3ume re3ponsibility to any party other than thè ch8ritsblo ¢ompany. the tharitabL8 company's rnernbers, a6 a body. and the charlty's trusteos, 88 a body, for our audlt work, lor Ihls report. or for tha opinlon we hav• fomied. Luk• Hoft Isonlor Ststutory Audltorl for and on behalf of Moore Klng8ton Smlth LLP Dèvon9hire House 80 GO$￿11 Road London EC1M 7AD Data.. 19 July 2021 23 Hyparlipidaemia Education Atheroscler08is Resèarch Trust UK (trading as HEART UK) (A company limited by guarantee) Contsolldated Slatomgnt of Financlal A¢tiviti•8 (Incorpora￿ng incom• and expenditure a¢¢ount} for the year •nded 28 February 2021 Unrn8trlctsd fund• 2021 R••¢rfctod Totsl fund• funds 2021 2021 Total funds 2020 Not• Incom• from., Oon8tion$, legacies alld grants Charitsble 8ctivltlO8 Trading incomè Other income Investment in¢omg 217,090 1B6,867 348,671 217.090 186,887 348,871 380,553 799, 743 523,504 24, T75 3,590 1.837 1,837 Total Incorn• 764866 754,46S 1, 132, 165 Exp•ndl¢ur• on: Raising fund6', Fundr8i8ing Exp6nditure from tr8dlNJ Charitsble activitsès 74.670 229,476 062 278 74,670 229,476 96, T74 419,021 6T2 OT5 Tot•1 •xp•ndbturo 866,323 886,323 1, 187,8TO t l•xp•ndlturg1 I Incorn• Not kJ88 on investments 1111,8081 1111.8581 (55,705J Ngt rnovgmont In fund• 1107,6041 1107,5041 f59,627) R•conclllatlon of fund6', Total lunds brought forward Total tund• ¢arrl•d forward 682,616 682,616 676,112 742,243 675,112 682,616 Th¥ note5 on pages 28 to 42 forrn part of Ih¢$& finan¢ial stgtemenis. All amounld afe derived from continuing aetivites. All gain8 and10sses rec￿nISed in th8 year are includgd above. 24 Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Con$olldated Balanc9 Shègt as at 28 Fobruary 2021 2021 2020 Note Flx•d a8Bots Intanglbla assals Tangible assets Invo$tsn•nls 13 14 30,874 19,773 52,816 44021 26,458 60,945 15 103.263 130,424 Curront a$*•ts Debtors 233,819 393,367 199,256 572, 177 Cash al bank and in hand 627,176 T71,433 Cr•dltor8.' llmounts lalllng due within ontr year 17 165 327 219 24t N•t ¢urr•nt a•8•t• 471,849 552, 192 N•t ••#•t• 676,112 682,616 Ch•rlly Fund• Restricted funds 18 Unr8strict8d funds 18 670,112 682,616 Total lund¥ 675,112 682,676 As perrnitted by s408 Companies Act 20C6, the company has not pres8nt8d ils own income 8ntJ expendiluie slalemenl and related noted. The company'$105s for the year was £107.50412020'. £59,627). The charlws financial $talgmgnls havg been prepargd in accordance wkh the provisions applicable lo companles subhect lo th8 small companies regirne. The Ilnandal slalements were approved and authorised for Issue by th• trustees on.1.71Q612Q2.l.. end slgned on Ihglr behalf. by.. Mr P Green, Chalrman illr N R Phlpp•, Trus The roles on pages 27 to 41 form part ofthese ffinancial statomonts. R8gist8r8d company numbèi". 02631049 25 Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Charlty balance sheet as at 28 February 2021 2021 2020 Noto Flx•d a88•ts Intsroible a58e Tanaible 8s$ets Invostments 13 14 30.874 19,773 43.021 26,458 15 fjQ.947 103,265 130,426 Curr•nt a•Mt• Detstors 108.094 744,353 Cash at bank and in hand 551,565 492,649 695,918 Crodltor•: amount5 falllng due ￿￿thIn one year 17 143 728 N•t curr•nt 4•••t• 552. 190 Not a6¢ots S75,112 682,81 Charlty Fund• Reslrtctsd funds 18 Unrastrictad funds 18 682 618 Totsl fund• 1175.112 682,616 The charfly'8 financial slalemenls have been prepared In accordance with the provlslons appllcable 10 companlos subjed to the small companies r8glme. 1710612021 The financi81 $lalemonts wgre approved and aulhorised for Issue by thg Iru$l¢gs on....... slgned on their behalf, by., and Mr P Green, Chalnnan hir N R Phlpp8, Trus Th8 nolas on pgges 28 to 42 form part ol these fin8ncial 3tsternents. Register￿ compsny number.. 02631049 26 Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company Ilmited by guarantee) Consolidated Ststemgnl of Cash Flo for the year ended 28 February 2021 2021 2020 Nots C•#h flow• from oporallng aetbvlti Net C8sh (used In)Iprovided by operating activits'es 1191.5031 (343,429) Ca8h Ilow* Irom Invègtlng actlvltl••.' Purcha3e ol inl8ngible fixèd assèts Purchase ol tangible fixed asge18 Purchas8 ol Iist8d Inv•stments 018PO8al ol Ilsted Investrnenls 13 14 15 15 (3,930) 125,826) (50,OOOJ 12,683 N•t c&•h u••d In Inv••tlng actbvltlag 12,883 (79,7561 Chang• In ei•h and ca•h •qulval•nts In tho y•ar Cash and Cash aqulv8l•nts brought f0Th￿rd Ci•h and ¢i•h èqulv4￿fttI carrl•d lorward 1178.8201 1423, 185) 672,177 393,357 995.362 5T2, 177 21 The note6 on page& 28 to 42 lomi part ol these flnancial 5¢atern?nl¥. An¥￿19 of Gon8olldat•d net rosourco• At28 February 2021 At 1 March 2020 Cash Ilow C88h al bank and In hand 572,177 1178,8201 393,357 27 Hyperlipidaomia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Nots8 to the fln3nelal stAtsmonts for the year ended 28 February 2021 1. Aceountlng pollcl•8 1.1 BaJl¥ ol prnparatlon of flnanclal 8tstem•nts Thè finanelal statamgnts have been pr•pai8d under the historical cost convention as modlfi'ed by the rèvaluation ol Investments to market valua and in compliance Mrith Accounting and Reporting by Charil'eg.. Statement ol Recommended Practi￿ applicable to charities preparing their fi'nancial ststernents in ccordance with the Financial Reporting Standard 102 including Upd8te 8ullets'n 2. 'The Fln8nclal Reporting Standard applicable In the United Kingdom and the Republic of Ireland. I'FRS 102.1 and thè Charities Act 2011. Hyp8rlipidaemia Educ8tlon & Atharosclèrosls Rasaarch Trust UK IHEART UK) Is a company limit•d by gu8rantse 8nd a r8gi$tgrgd charily and incorporated in England and Wala$. HEART UK meets tha dèllnit'on 018 publlc ben8fit •nlity under FRS 102. The financial stslements are prepared In sterlin9 whith is th? funcfional currency ol the Group. Monatary amounts In these flnanci&l 8lat8ments are rounded to the nearest pound. The Statement of fy'nancial activities ISOFAI and 8alance Sheet consolidate the financi81918tsm?nt3 of tho charity and it3 ¥ubsidi8ry undèrtaking. Tha rèsults oltha subgidisry arè consolKJatad on a line by lina bag18 and the detsiled results are di¥clos¢d In not• 24 01 Iho financial stsl•m•nts, HEART UK has taken advantage ol the exemption in Section 408 01 th8 Companie5 Act 2008 Irorn disclosing its individual 5tatemgnt of financial adivilie3 The HEART UK onw deficrt Ingl movgmenl in funds) was1£107,504112020. £59.6271. 1.2 Golng conc•m The trustees have a58es3ed whether tha use ol the oolng concern basis is approprlats and havs considered possible event5 or conditions that might ¢a$t 819nificant doubt on tho ability of thè company to conh'nue as 8 going conc8m. The truste88 hav8 made this asses8ment for a p•ii¢d ol gt least ona y8ar from the date of 8pprov81 ol tht financial 81atèmènt8. In particular the Iruslèès hava con3idgr8d the ¢omp8ny'$ lorèeAsts and prolacttons and hav8 taken account ol th8 Coronavirus pandernle. company had 8daquate resources to continue In 0￿ratiOn lor at least twelve months from the approval ol the rinancial stat•m•nts. The company therefore continues to adopt the going concem basis in preparing its finanda1 statements. 1.3 Fund •¢countlng GeTh8ral funds are unr85tricted funds whlch are available for use al the di3cfetion ol thg tru¥te¢$ in furtherance ol the general objects'ves of the charty and 4vhich have not b8en da8ignatsd for other purpose Restrict&J fundB are hJnd8 ￿1¢h 8r¢ t¢ b• uséd In aeeofd8n¢e wth speclfic w$lri¢tion8 Impos8d by donors or which havo baèn raised by Ihè charity for particular purposè8. Tho ¢o$ts of raising and administaring Such lund$ ara ¢h8rgad again$1 th• ydlic fund. Tha gim and usè of ¢4¢h restricted fund is sat out in the notss to the linanoal slatefflents. Th058 funtjs which are not ¥8strict•(J income funds, are unrestricted inwm8 lunds which are sub 8nalysed b9￿n designated funds, where trustees have set aside amounts to bè used lor Specific purposes or lh￿￿ raflèct tha non-bindlng S￿$￿8$ ol donors.. and unresknct8d funds. whlch are used at the trustses, discretK)n in furtherance of the gereral objecl'v83 of HEART UK. 28 Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantae) Notes to the financlal ststem•nts for the y¥ar ended 28 February 2021 1. A¢¢ountin9 poli¢kn3 Icontinuedl 1.4 Income All income is recognised OTh￿ the charity has entitlement to the income, it is probable that the income wll be rec8ived and the amount of inc4me receivabl8 can be measured rdiably. For1893ck88. entl￿ement 15 takan 85 the earlier of th8 dat8 on which elthgr.. th8 charity is ?war8 that probats as teon gr¥ntod. th8 e$tst¢ has boon linali$?d ¥nd n¢lification ha¥ been mado by tho èxecutorlsl ta thè Trust thet a dislnbulion will be mad¥, or when 8 dislnbulion i¥ rgBeivgd from the $$tat& Re￿Ipt of a legacy, In wholè or In part, is only consldèrad probablè whèn tha amouni can ba Measur￿ rall8bly and tha chadty has baen notified ol the executo¢s intsnlion to make a distributs'on. Where legacies have been notified to th8 charity, or th6 charity Is awar• ol th• granting ol probate, and the cnteria lor Incom• recognrtion h9¥8 not bean met, then Ihe legacy 18 treated aB a conts"ngent 8sset &nd disclosed il material. Donated 8¢rvices or l¥ctlilio$ aro rewgnised when th? ch?rity h85 control over Ihg il?m, any ￿ndItionS 8980elat￿ with Ihé donatèd tt8m h8va béen mèt, tha rècèipt tslt¢¢nomic bènèfi't from tlw usè of th& chgrity ol the item Is probable and that èconomie benefit can be maasured reliably. Donated s•rvlcas ara valuad at tha 8mount HEART UK would ba praparad to pay lor a simi18r sèrvlcè. Interest on lund5 held on deposit is included when receivable and the amount can be measured reliably by th¢ ¢h¥rily', thi$ 1$ normally upon notifi¢ation tsf the inler•$l or payabl• by th* bank. Incom¢ tsx re¢ov8r8bl* In rglallon to fJonatlon$ recelved under Glft Ald or ¢Jegd8 of covgnanl 1$ rg¢ognlsed at th• lim• ¢1 tho donation. Trading incorne represents turnovèr In the trading subsidi8ry which consists ol confèron¢e 8ponsotships. debgate Income. product licence lees and other services and are accounted net ol any discounts and ex¢luBive ol value added tax. 1.5 Expgndl¢ur• Expenditure is recogn18ed once there 18 a legal or constructive obligation to transfer economic benefit to o third party, il is probable Ihat a transfer of economic t*nefils will be required in settlement and lh8 amount ol the obligation can be rneasured reliably Expenditure is classified by activity. The cosb ol each activity are made up of the tot81 of direct costs 8nd shared costs. including Bupport Costs involved in undertsklng each activlty. Direct costs altrlbutable to a single acl'vity are alloc8led direcly to that activity. Shared COBts which ¢¢ntribut8 to mor8 than one 8cts.vity anij support costs which are nol attributabl810 8 5ingl8 activity are apportioned b&tsv¢¢n thoso a¢livili¢$ on a ba$1$ unsi¥l¢nl with the use of resour¢￿. ¢*nlr¥l glall ￿¥ts a alkicgled on the b83ig of tirne jpenl, and depreci811on charge3 8lloc8ted on the portign of th¢ 83¥el'3 U¥0. Costs of ganargting lunE1s ar• costs Incurred in attracting volunt8ry incomè, and thos• Incurr•d in trading Artlvlli&* IhAt raisè Iijnd*. Charrtab18 aCtivit18s are c05t5 Incurtad on the ehurftys aducalDnal opèrations, including gupport costg 8PPOrtion8d to charitsblo 8¢1iviti•$. 1.6 Operatlng lea$08 Leases thatdo not transfer all Ihe risks and rewards of ownership are dasslfied as operating leases. Payments under operating leases are charged to the SOFA on a straight line basis over the period ol the ase. Incenl'ves received to enter into operating leases are credited lo the SOFA to reduce the lease expense, on 8 straight line basis over the period of the lease. 29 Hyperlipidaemia Education Atherosclerosi8 Research Trust UK ltrading as HEART UK) IA company limited by guarantee) Note$ to th• finan¢lal statsmfjnts for the year ended 28 February 2021 1. Accountlng pollcl8s Icorttlnu•d} 1.7 Employe• bèn•flts Thg charity operat88 8 defi'ned contrlbution P?n9ion gnd daath In sarvK8 schem8. The pensl¢n chargè r*pr&sgnts th• amount5 payable bv th8 charity to th8 fund In r•sp8ct ol the year. 1.8 Intsnglble fix￿ a•¥ets and amortS8atlon Intangible a55els arg ¢apltalised and recognlsed when lutUTe economic benefits 8r• preA)8bl& and Ihe cost or value of the 858at ¢an be measuffjd reliably. Intangible assets are initially rgcogni$ed at cost and ar8 8ubsequgnJy ma8sur8d 8t cost net of 8mortisalion Bnd Any provi8ion lor Impalm)enl. Intsngibl? a$$*ts ara capitlised where the purchase price exce*d$ £500. Arnorti3?Ilon 1$ pmvlded on intangible ￿Xed a88ets at r4t98 cèlculatad to wrftè off the cost of each 88set,1è88 theiresYfflatad ra$ldual value, over their expectsd useful Ilv6s on Ihe followin9 bos•8.' WebBite devdopm•nl 20% straight Iln• 1.9 Tanglblo Ilx•d 41••t• And dgpr•¢l•tlon Tangible fixad asset6 are carriod al ost. nat ol daprècla￿on and any provision for Irnpairment. Depreciation i¥ provided al rate5 C81culaled lo write orr the ¢¢$1 ol fix•d a$￿ts. 1888 th•Sr88timat8d residual valu•, ovar their expected usefvl lives on tha lollowng bas•s. 'I"angible a88•t8 aro Copi￿1$8￿ wh818 the purchase price exceeds £2bO, Office equlprnent Computar equipment 15% straight line 33% straight line 1.10 Flx•d a•••t Inv••trn•nt• Flxed as501 invo8trnènts aro a form of financial instrument an(J are in￿allY recognised al their tr8nsactlon cost and subsequenlly mea$urod 8t falr va1u6 at the bglance sh￿t date. unle8s lair value cannot b8 mèasured reliobly in which cBse 11 is messured at cost less Impalmient. Investment Gains and1055es. whether r6alls8d or unrgalisèd, are eombined and shown In the heading 'Net galnslllossesl on lrtvèstm•nts' in th8 Statement of linancial a¢bvTti08. Tha invesbment In Bubsidk2ry is valu8 at C061. 1.11 D•btor• Trade and oth8r d8btor5 ar8 recognised at the settlement arnount after any trad* dis¢¢unt offered. 1.12 Cash it bank and In hand C88tt at bank and In hand indude5 cash and short 18rrn hyhly Ik]uid invo8lmen¢s wlth ¥ Short rna￿rfty of three rnonlhs or le$s from the date ol acquisition or op8nirvJ ol the deposit or Similar 8¢count 30 Hyperlipidaemia Educatlon Athorosclero8i8 Research Trust UK (trading as HEART UK) (A company limitsd by guarantee) Nots$ to the finan¢lal statemènts for th• y•ar èndod 28 February 2021 1. Aeeountlng ptsliel•8 l¢ontinuedl 1.13 Flnancial Instruments The ch8nty only has fin8nci81 a53ets and financial liabiliti88 ol a klnd that qualify as ba$1¢ fin¥noal instrL¥nents. Ba$1¢ fin8n¢ial instruments are initially recognisgd at transaction value and subs8qu•nly maasursd 8t thèir satuamènl value wth exception ol bank loans whlch arg subsaquontly measured at amortised cost using tha eff8ctiv8 Int•r•st method. 1.14 Crlllcal a¢countlngludg•m•nt• and ••tlmatlon une•rtalnty Estimates and ludgrnents affj conlinu81ty avaluated and 8re b888d on hi8iori¢81 experience and other factors, including expectations ol lutura events that are bèlièved to b• re¥3onable under the circum318nces. Slgnificanl a¢counlin9 iud9•rn8nts and e81imate5 include.. • Le98¢y $xrued incorne Depr￿la1.0ll and Bmortisation rat89 CVD Accrued income . Uaoful •eonoml¢ Ilv•• of tanglblo and Int•nglbl• a••ots The 8nnual depreciation and 8rnortisalion charge for fixed ass•ls IS 88nsitive to ¢hang8s In the èslim•l•d useful aconomic Ilves of tho a$¥¥t$. The u8glul econornic Itve8 are r8.as8es86d annuglly. These a amended where necg8sary to rsfle¢t ¢urronl estimates. based on technological advancamènl, futur& In￿$trnent$. aconornlc ulilisalion and tha phy$i¢•l ¢ondilion of the assets. Soe notes 13 and 14 lor the carrying vglue of assats and nolg 1.7 and 1.9 for thè useful èconornic lives. 31 Hyperlipidaemia Educatlon Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Note8 to tha financial ststements for the year ended 28 February 2021 Income from donation8, 1•gac1￿ Ind grants Unro¥trl¢t•d fund8 2021 Re8trfcted fund* 2021 Total lund8 Totel funds 2021 2020 Donatlons Legacie5 Gift aid 170,148 37,000 9,942 217,090 170,148 37,000 9,942 217,090 190,231 180,000 ILI,322 Total doThation$ and ￿9￿CloS 38Q,553 Tolg12020 380,553 380,553 Charltsblo a¢tlv5tlo8 Unr••trlet•d fundB 2021 Re•trbct8d fund¥ 2021 Tot¥1 fund• fol81 funds 2021 2020 Fundra19ing 186,fj67 186,867 199, 743 186887 186,867 t99.743 Tol812020 199, 743 199.743 4 Tradlng Income Unre8trlctsd fundB 2021 Re8trlct•d fund• 2021 Totsl fund• Total funds 2021 2020 Income from tradlng Subsidiary 348 671 Pleasg $9e noto 24 for detsils ol tha trading subsidiary in¢om•. Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notes to th* flnan¢lal ststom¢nts lor the y•ar ended 28 Fobruary 2021 Ot￿r Incom• Unrestrlclgd fund8 2021 R•8trlctod lund8 Total lunds Totalluncls 2021 2020 2021 Sponwrship and other Incorne 24, TTS Total 2020 24, 115 24, 775 Invè8tm•nt Incom Unre•¢rl¢ted fund• 2021 Ro8trl¢t•d lund8 2021 TotAI fund• Total funds 2021 2020 Dividend r•¢?ived Inlere8t received 187 1,650 187 1,680 835 2, 755 1,837 1,837 3,590 Tot812020 3,590 3,590 7 Ral$lng funds Unro•trl¢ted lundg 2021 Re•trlct•d funds 2021 Total fund• Totalfunds 2021 2020 Stsff c08ts Other fundraising ￿$ts 46.334 28.236 46.334 28,236 57,914 38,860 T¢t81 74,570 74.670 96, 774 Totel 2020 33 Hyperllpldaemia Education Atherosclerosis Research Trust UK {trading as HEART UK) IA company limited by guarantee) Notes to the financlal ¥tstsments for th• y•ar •nd•d 28 February 2021 Tradln9 ¢￿ts Unr•strlct•d funds 2021 Re•trlc¢gd lund8 2021 Total funds 2021 Tot81 lunds 2020 Staff costs Direct costs Administrat￿ •xpèns&s 59,378 129,477 40,620 69,378 129,477 40,620 59,415 309,488 50.118 Tol&l 229,470 229,4711 419,021 Charltablo a¢tlvltl•s Unr••trlct•d fund• 2021 R••trktod fund 2021 Tot41 fund• 2021 Total lunds 202Q Awar8nesB, edu¢alon ond p8ti•nl support Govwnan¢e ¢¢$15 Inote 101 537,297 24.981 637,297 655,803 $82,278 662,278 672,OTS 10 Gov•rnanc• costs Unrn•trlet•d lund• 2021 R￿trIct•d fund• 2021 Total fund• 2021 Total funds 202Q Audlt and accounlan¢y fee$ 24,981 24,981 16,212 11 Not movoment In fvnds Th59 Is stst8d after chargirvj.. 2021 2020 Depreu8bon oltangible fixed a5sets'. Arnorh5al'¢n of intangible fixed a5s9ts Auditor's remun$raJon- audrt Auditor'8 r8muneration- non audit 88rvic8s 8,302 11,352 12,698 8,690 11,096 12,450 Hyperlipidaemia Education Atherosclerosis Research Trust UK {trading as HEART UK) (A company limited by guarantee) Notes to tha financial statom8nt8 for the year 8nd•d 28 Fbbruary 2021 12 Staff costs 2021 2020 Wag88 and 8alari8S Soclal security costs Other pension costs 332,457 34,979 17,643 340,443 32, 135 16,306 384,979 388,882 The averagg number of full.time •quivalent employees lincluding casual and part liwE stsff) duTing the year was made up as follows.. 2021 No. 2020 Charitsble operallons Manapmenl and cgnlral seNIc•s Th• number of employ9¢8 vthose remuneration exceed £60,000, Is shown below.. 2021 No. 2020 £80,000 to £69,999 Koy mana9gmenl personn•l ¢onsl$ts ol the l•ader8hip m8n8gemenl team and con315ts of four12020'. 4 Individuals. Total remuneration to key management personnel lo¢alled £239.373 in the year12020.. £211,221). DurlrwJ the year total travel 8xp8noa8 of £Nil12020'. Q,3e51 wgrg relmbursed lo 012020.. 81 Trustees.). 13 Intanglble flxed a8set8 d9Volopmont Group and Charlty Cost Al 1 March 2020 DiBpo8818 Al 28 Feixuary 2021 Amortisatlon Al 1 March 2020 Charge for the year Elimin81ed on disposal$ At 28 February 2021 C8rrying amount At 28 February 2021 56,7S8 1,2591 66,499 13,738 11,352 14631 24,625 30,874 Al 29 February 2020 43,021 35 Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK (A company limbted by guarantee) NoteB to the Ilnanclal ¥tst•m•nts for the year endèd 28 February 2021 14 Tangiblo flxod assets Offle• Computsr •qulpmont aqulpmont Total Group and Charlty Co8t Al 1 March 2020 Di$posals At 28 F8bruary 2021 D•preclatlon At 1 M8rch 2020 Charge lor the ye Ellminatèd on dlsp05al 43,181 19,4281 19,890 19,485 63.071 -28,913 33,753 405 34,168 17,093 6,095 9,045 19,520 207 19.4e5 30,613 6,302 -28,530 At 28 F•bruary 2021 14,143 242 14,3811 Cwrrylng Amount At 28 February 2021 19,810 183 19,773 Al 29 February 2020 26,Q88 370 26,458 1S Flxod assot Invo•tmonts Group 2021 Charlty 2021 2020 2020 Inv88tments at market value Investment in subsidiary at cost 52,e16 60,945 52,816 60,945 52,616 60,945 62,618 60,947 2021 2020 M4vket v#lu• At 1 March 2020 Addltions Oisposals Nel gainsll l¢ssesl At 28 Fabruary 2021 80.946 14,867 50,000 112,6831 3.922 60,945 52,616 Hlstodcal cost of listsd investments 36 Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notes to the financial stat•mènts for the year ended 28 February 2021 15 Flxed asset Inv•stm•nts Icontlnuodl Slgnificant Invefjtment holdlngB baeed on market value at 28 Ffrbruary 2021 were.. Hl8torlcal co8t8 Mark•t valu• (£1 1£) M&G Equities Investment Fund COIF Ch8rllies Investment Fund 14.514 50,000 64,514 52,617 52,617 16 0•btorn Group Charlty 2021 2020 2021 2020 Trade debtors Arnounls owed by group undert8klng8 Other debtors Prepayments and accNed Income 55,100 30,071 10.500 18.508 4. 182 10,429 168,819 169, 185 85,694 140, 771 AmountB due over 1 year Prepayments and accrued Incom6 9,900 1443S3 17 Crèdltorn: Amount8 folllng du• wlthln ong ygar Group 2020 Charfty 2Q20 2021 2021 Trad8 crndllors Amounts owed to group undertaklngs Other taxation and 8oclal securtty other creditors Accruals and deferred Income 81,190 114,580 10,808 21, 138 TO,57 1 8,946 1, 854 41,279 143, 728 8,702 3,240 72,624 9,373 1,854 93,434 219241 8,702 3,240 18,460 Deferred Incom8 In th8 charity relates to Income to support for future events and are Includad in cr8ditor8 81 the perlod end. Defgrrad income on a group bo$1$ Includ$$ $pon$orshlp and licenee income eamèd in the subsequant financial year. Group d•f•rr•d Incom• Brought forward Amount added Amount r•lèasgd Carrl•d forwar¢1 Oeferred income 2021 eo,181 80,181 41,101 Del&rr8dincome 2020 149,952 60, 787 149.952 6Q. 781 37 Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Nots8 to the flnanclal statements for the year ended 28 February 2021 18 Stat•ment of fund8 a. Group Ngt g•1 Balance at and 28 February tran8fer8 2021 Bal•nc• •t 1 March 2020 Income Expondltur• Dgslgnated fund8 Dosignaied funds- 811 fiJnd8 142,747 142,747 Goneral fund• General funds- all funds 639,869 682.616 764,485 764,486 1866,3231 1866,3231 147,101 675.112 Total unrestricted fvnds 4,364 67S.112 Re•trl¢t•d lund• Rg$trictad funds- 911 funds Total ol lund$ 682,618 764.465 1866,3231 4,354 576,112 N•1 g¥ln¥ 8al4neo al 4nd 28 Fgbruary tr&n•f•rn 2021 . Ch•rlty 8al¥nc• It 1 Mareh 2020 Incom• Expènd1￿r¢ 0•¥19nat•d fund• De¥pn8ted funds . all funds 142.747 142,747 G•n•rnl fund• Genèral funds- all fundg Total unrestricted fund$ 639,869 682,816 624.990 524,990 1636,8481 1636,848 147.101 4.354 576,112 575,112 R￿trIcted tund8 Restricted funds- 811 lund8 Total of fundB 682.616 575112 Dfr61gnat0d fund• In February 2019. Ihe Charity rgceived a legacy from Isabella Cathright for the sum of £142,747. The Trustees wanted lo jet aside the mon8y to be used toward5 the charities new 8rnbits'ou5 Strategy to support anyone in the UK who h85 8 lipid probl￿. Around 25.000 people are identified as h8viro 8n inherltad lipid condition and it h8S t8keA 30 years to get to this number. Thèrè 8rè thousands morè pèoplè unldèntified and we aim to double thè numb8r to 50,000 by 2023. In order to achieve thase object￿S we n6ad to shapa organisation and our servi¢0$ lo ensure we can help Ihousand3lmillion5 more people with lipid is5u•, whether inherited or not. This lund w85 untslised during the 2021 fi'nan¢ial ￿>r. Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notes to th• financial statsmonts for the ygar gndod 28 F9bruary 2021 19 Ana￿￿5 of Mt a$s•ts botween funds Group Unre•trl¢t•d funds 2021 Total fundg 2021 R•$trlct•d fvnds 2021 Intangible Irx8d assets Tangible fixed 85sets Fixed asset invesbnants Currènt 8SX•ts Creditors due wthin one yoar 30.874 19,773 52,616 627,176 1105,3271 676,112 30.874 19,773 152,616 627,176 11116,3271 576,112 Charfty Unrg•trlct•d lunda 2021 Rutrlct•d fund• Total lund• 2021 2021 Intangible fixed a398ts T8NJible fixod o$$•ls Flxed a3881 investment8 Curr8nt ass*ts Credrtors due withln one ye&r 30,874 19,773 52,618 492,549 120,7021 67S,112 30,874 19,773 52,618 492,549 120,7021 576,112 20 Rtr¢onciliation of net movèmènt in fund8 to ntrt cash flow from opgrating actlviti•s Group 2020 2021 Net Ideficit)lincome lor th8 yoar185 por Statem•nt of Fingncial aCt￿lt[S5) Adlu8tm•ntlor'. D8preciation charg85 Amortisation chargas Nat lossos Profit on sale of fi'x8d assets Increase in debtors in¢r888e in eThlitors 1107,5041 (59,627) 6,302 11.352 14,3541 1.178 134.5631 163,9141 1191,5031 8,690 I 1,096 3,922 (84,665) (242,845) (343,429) ¢•$h lu••d Inyprovld• by op•ratlng actSvWe• Hyperlipidaemia Education Atherosclerosis Research Trust UK Itrading as HEART UK) (A company limited by guarantee) Notes to the financlal ¥tstsm¢nth lor th• year ended 28 Febn￿ry 2021 21 An8lysSs of ciah and ¢a8h •qulvalonts Group 2020 2021 Cash in hand 393,357 572, IT7 Total 393.357 572, ITT 22 Ponsion commltments Thè group operates a defined contribution3 pen3ion $chorn8. Tha pension co81 charg8 in tho y88r represenfs contrlbulons payable by thg group and amtsunte(I to £17,54312020'. £16,306). 22 OptrrAtlng l•a•• ¢ommltment• At 28 February 2021 the lotsl future minbrnum 188so p8ym•nts undér non-canc8llabl• op8r&ts'ng le83es w8$- 2021 2020 Group •nd Ch•rlty Wbthln l y¢ar Bglw•8n 1 and 5 yearB Totsl 27,426 1,889 26,2Jf7 1,887 28.138 29,314 40 Hyperlipidaemia Education Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Note8 to tho financlal statements for the year •nd•d 28 February 2021 23 Relatsd party transactlons Som$ of the Iru81998 hgld p08ition8 wlhin organisations wlh which HEART UK has links. Some ol those organisation5 ffl8y make don8tlOllS to. or seek product approval licenses frorn the charlly or its trading subsidiary. The charity has 8 conflict ol interest policy in plae• to 8nsur• that potsnts'al conflicts 3r8 idenb'fied and dealt wth appropriately. For the current and pracadln9 yèar 811 trAnSac￿On$ with thèsè wlated parties are considered wthin tho scop8 01 normal tr&n8actions. An incorne distribution was made from HEAR T UK Trading Company Limitèd, 8 wholly ownad subsidiary. lo HEAR T UK of £114,79412020'. £104.4831 being a distribution 01100% 01 their net profit In the year. In addition, HEAR T UK Trading Company Llmited was recharged salaries ol £59,37812020'. £S9,4151 from HEART UK. AI the year end an amount of £21.83612020', £.70.5111 wa8 owed by the subsidiary. Durlng the yaar, FH Europe. a charitable incorporgt8d org9nis81ion rglatgd to HEART UK through ¢omrnon k9y manag8m•nl, was charged management faès iot8lllng £Nil12020. £37,713). Thè m8nag¥m*nl f•• cov$r$ n re18tion to the use of HEART UK'S staff and resourc88. Included within debtors at year •nd Is £NIl12020". £9,712) owed from FPI Europe, 24 Prlnclpal Subsidiary HEART UK has one wholly owned subsLd18ry, HEART UK Tradlng Cornpany Llmitgd. whi¢h a¢t$ 89 thè tr8ding subsidlary ol th8 group and has been Includad In Ihls sat ol consolidated Ilnancig1518taments. Tha eomparty has entered into 8 deed of covenant to donal8 ils disthbutsble prolrts to HEAR T UK. The r8glslered offlce ol the subsidiary IB 7 North Road. Maidenhead, Berkshire. SLe 1PE and Its company numbar is 03679100. A summary ol its trading results are shown below. A Bet ol audited Ilnancial Stalernents for thls subsidlary are filed annually with tho R¢gi$tr8r of Companies. HEART UK Tradlng Company Llmlt•d r•8uIt• 2021 2020 Prollt and108• Tumover Cost ol Salo8 AdmlnI*tratl￿ Expon••• 344,268 1111,8821 1117,5901 523,504 (304,876) (t t4, 145) Op•r4tlng prollt 114 796 104,483 Reeonelllatlon ol prolbt and1088 r•••m8 Brought forward Operatlng proflt Dlstributlon to HEART UK 114,796 1114,7961 104,483 (104.483) C¥rrl•d forward No ch8rg0 to i#X8tion will arise as the subsidiary ecmpany has entered into a deed of covenant to donate its dislribLrtablg profits lo its charitable parent HEART UK. 41 Hyperlipidaemia Education Atherosclerosis Research Trust UK {trading as HEART UK) IA company Ilmited by guarantee) Notes to the financial ¥tatement• for th• y•ar gnd•d 28 F•bruary 2021 24 Prlnclpal subsldlary Icontlnugd) Bal•nc• Sho•t: 2021 2020 Curr•nt a•￿t$ Oebtors Cosh at bank and in hand 127.726 6,902 134,627 125.414 20,612 144026 Crgdltorn.. amcojnts falling duo vAthin ono yèar 116 117 146 Q24 N•t curr•nt a•••t• 18AI0 Capltal and rn8•ry•4 Called vp sharo eapital Tot•1 Equlty Thft AharA r.ApifHI rftprAAAnlJ ?. C)rcJinxry Aharns of £1 8ach h81d by HEART UK. 26 Llmlted Ilablllty HEAR T UK Is o company limited by gu¥rants8 and 88 8uch do88 not hav8 shafe Copltal. In the &vonl of wndlng up tho Iiaknlity oleach m•rnbar is limitwj lo £1,